Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a …

…, EMJ Brouwers-Kuyper, AHH Bongaerts… - The Lancet, 2002 - thelancet.com
Background Diagnostic strategies for pulmonary embolism are complex and consist of non-invasive
diagnostic tests done to avoid conventional pulmonary angiography as much as …

ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody–drug conjugate treatment

…, JA Gietema, CP Schröder, AHH Bongaerts… - Clinical Cancer …, 2016 - AACR
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers,
making it a potential drug target. We performed an 89 Zr-PET imaging study with …

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

…, TH Oude Munnink, AH Brouwers, AHH Bongaerts… - Clinical Cancer …, 2014 - AACR
Purpose: HSP90 chaperones have key client proteins that are involved in all hallmarks of
breast cancer growth and progression. The primary aim of this clinical trial was to evaluate the …

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic …

…, WJ Sluiter, RA Dierckx, AHH Bongaerts… - Journal of Nuclear …, 2015 - Soc Nuclear Med
No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell
carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be …

Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT

…, HJG Arts, NM Jager, AHH Bongaerts… - Journal of Nuclear …, 2015 - Soc Nuclear Med
The estrogen receptor α (ERα) is expressed in approximately 70% of ovarian cancer tumors.
PET of tumor ERα expression with the tracer 16α- 18 F-fluoro-17β-estradiol ( 18 F-FES) may …

111In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment

…, THO Munnink, AHH Bongaerts… - Molecular …, 2014 - journals.sagepub.com
Human epidermal growth factor receptor (HER)2 imaging with radiolabeled trastuzumab
might support HER2-targeted therapy. It is, however, frequently questioned whether HER2 …

Everolimus reduces 89Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors

…, AH Brouwers, AHH Bongaerts… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Everolimus increases progression-free survival in patients with advanced neuroendocrine
tumors (NETs). Currently, no biomarkers are available for early selection of patients who will …

18F-fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients

…, EFJ de Vries, AHH Bongaerts… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However,
knowledge about varying expression across metastases and surrounding normal tissue in …

Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies

…, AWJM Glaudemans, AHH Bongaerts… - Journal of Nuclear …, 2017 - Soc Nuclear Med
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor
receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment…

Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients

…, A van der Schaaf, LV van Dijk, AHH Bongaerts… - Radiotherapy and …, 2016 - Elsevier
… Smeenk et al. were the first to try to find an explanation for these incontinence related
complaints by analyzing the relationships with the dose to different pelvic floor muscles by means …